A share price of Jazz Pharmaceuticals plc [JAZZ] is currently trading at $136.05, up 1.41%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The JAZZ shares have lost -0.29% over the last week, with a monthly amount glided 4.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jazz Pharmaceuticals plc [NASDAQ: JAZZ] stock has seen the most recent analyst activity on March 07, 2025, when UBS upgraded its rating to a Buy and also boosted its price target to $179 from $145. Previously, Cantor Fitzgerald downgraded its rating to Neutral on February 26, 2025. On February 13, 2025, upgrade upgraded it’s rating to Overweight and revised its price target to $170 on the stock. Morgan Stanley upgraded its rating to a Overweight and increased its price target to $175 on December 12, 2024. Goldman initiated its recommendation with a Buy and recommended $169 as its price target on June 05, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on January 03, 2024, and assigned it a price target of $160. In a note dated November 27, 2023, UBS downgraded an Neutral rating on this stock and revised its target price from $170 to $135.
Jazz Pharmaceuticals plc experienced fluctuations in its stock price throughout the past year between $99.06 and $148.06. Currently, Wall Street analysts expect the stock to reach $175.25 within the next 12 months. Jazz Pharmaceuticals plc [NASDAQ: JAZZ] shares were valued at $136.05 at the most recent close of the market. An investor can expect a potential return of 28.81% based on the average JAZZ price forecast.
Analyzing the JAZZ fundamentals
Trailing Twelve Months sales for Jazz Pharmaceuticals plc [NASDAQ:JAZZ] were 4.07B which represents 7.53% growth. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.14 and Total Capital is 0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 134.64 points at the first support level, and at 133.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 137.90, and for the 2nd resistance point, it is at 139.74.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Jazz Pharmaceuticals plc [NASDAQ:JAZZ] is 4.46. Also, the Quick Ratio is 3.99, while the Cash Ratio stands at 2.32. Considering the valuation of this stock, the price to sales ratio is 2.03, the price to book ratio is 2.01 and price to earnings (TTM) ratio is 15.55.
Transactions by insiders
Recent insider trading involved Iannone Robert, EVP, Global Head of R&D & CMO, that happened on Mar 10 ’25 when 2403.0 shares were sold. SVP, Chief Accounting Officer, Carr Patricia completed a deal on Mar 10 ’25 to sell 1140.0 shares. Meanwhile, Officer Iannone Robert bought 1767.0 shares on Mar 10 ’25.
